Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection3회분의 BNT162b2 백신 또는 BA.1 감염에 의한 Omicron 하위 계통 및 Deltacron SARS-CoV-2 중화Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 임상, 진단, [키워드] Antibody neutralization BNT162b2 BNT162b2 vaccine contribute convalescent sera dose evade geometric mean geometric mean titre geometric mean titres GMT GMTs highest Identifier immune immune evasion individual infected individual infected individuals Infection Mutation neutralization neutralization activity neutralized of BNT162b2 omicron post-dose SARS-CoV-2 SARS-CoV-2 spike sera titre Trial registration unique USA-WA1/2020 vaccinated individual Vaccine variant variants variants. [DOI] 10.1080/22221751.2022.2099305 PMC 바로가기 [Article Type] Article
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trialArticle Published on 2022-12-012022-10-06 Journal: The Lancet Regional Health - Western Pacific [Category] 진단, [키워드] acute respiratory syndrome Administered Adults adverse event AEs age analysis assessment assigned BNT162b2 BNT162b2 mRNA BNT162b2 mRNA vaccine China Chinese clinical trial Complete Completed conducted coronavirus COVID-19 development dose double-blind Efficacy and safety enrolled Follow-up geometric mean titer GMT GMTs Han Chinese healthy immune response immunogenicity immunogenicity endpoint Inc independent individual injection intramuscular Intramuscular injection investigators Laboratory parameters management messenger Messenger RNA Mild moderate mRNA vaccine Neutralising Antibodies neutralising antibody of BNT162b2 participant Participants pharmaceutical Placebo placebo-controlled trial randomisation randomised Randomly reactogenicity receive recipients recruited reduced remained reported resolved Result robust Safety SARS-CoV-2 SARS-CoV-2 variant SCR second dose sera serious AE seroconversion rate severity Shanghai Sponsor statisticians stratified T-cell Response the placebo group Tolerability Treatment Trial utilised vaccination vaccination. vaccine administration were blinded [DOI] 10.1016/j.lanwpc.2022.100586 PMC 바로가기 [Article Type] Article
Safety, immunogenicity, and immune persistence of two inactivated COVID-19 vaccines replacement vaccination in China: An observational cohort studyArticle Published on 2022-09-162022-11-15 Journal: Vaccine [Category] SARS, 진단, [키워드] administration Adverse reaction All participant anti-SARS-CoV-2 approved BBIBP-CorV can be used China Complete control group COVID-19 COVID-19 vaccine Cytopathic effect dose doses first dose geometric mean concentration geometric mean titer GMCs GMTs healthy immune persistence immunogenicity Immunoglobulin inactivated Inactivated vaccine Mild mitigate moderate NAb National not different not significantly different observation Observational cohort study Pragmatic regimens replacement Replacement vaccine Safety safety profile Safety. SARS-CoV-2 strain second dose sera severity Standard subject vaccination WHO [DOI] 10.1016/j.vaccine.2022.08.037 PMC 바로가기
Kinetics of anti-SARS-CoV-2 antibody titer in healthy adults up to 6 months after BNT162b2 vaccination measured by two immunoassays: A prospective cohort study in JapanArticle Published on 2022-09-092022-11-15 Journal: Vaccine [Category] SARS, 진단, [키워드] Abbott acute respiratory syndrome Adults age anti-RBD Anti-RBD antibody anti-RBD antibody response anti-receptor-binding domain anti-SARS-CoV-2 antibody Anti-SARS-CoV-2 S antibody Antibody Response Antibody titer Architect Architect SARS-CoV-2 IgG II Quant assays blood sample BNT162b2 BNT162b2 mRNA vaccine BNT162b2 vaccine collected comparable Coronavirus-2 correlation dose Elecsy Elecsys Elecsys Anti-SARS-CoV-2 S evaluated first vaccination geometric GMT GMT ratio GMTs healthcare healthy immunoassay immunoassays Japan Kinetics mRNA vaccine mRNA vaccine. no significant difference Older age Participants prospective cohort study RBD Roche Diagnostics SARS-CoV-2 SARS-CoV-2 IgG second vaccination Sex significantly lower Spearman vaccination were measured [DOI] 10.1016/j.vaccine.2022.08.018 PMC 바로가기
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 studyClinical Trial Published on 2022-09-012022-10-05 Journal: The Lancet. Infectious Diseases [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] 95% CI Administered Adults adverse event age all age group antibody baseline Bharat Biodefense children clinical conducted COVID-19 vaccine curtail deaths decrease demonstrated dose Efficacy eight eligible Endpoint enrolled female Fever for inclusion geometric mean GMT ratio GMTs group groups healthy children hospital Hyderabad immunogenicity immunosuppressive inactivated Inactivated vaccine India Infection injection site pain intramuscular dose less Local local reaction male Mild Mild-to-moderate multicentre neutralisation test neutralising antibody response neutralising antibody titre no difference Open-label Pain pandemic participant Phase 2 study phase 2/3 platform positive PRNT Reactions reactogenicity reduction Registered registry reported safety profile SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 nucleic acid SARS-CoV-2 vaccine second dose Serious Adverse Events seroconverted serology test serum sample severity of COVID-19 susceptible Symptom three group titre Trial were excluded Withdrawal [DOI] 10.1016/S1473-3099(22)00307-3 PMC 바로가기 [Article Type] Clinical Trial
Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-AnalysisArticle Published on 2022-08-292022-11-15 Journal: International Journal of Environmental Research an [Category] SARS, 변종, 진단, [키워드] 95% CI 95% confidence interval acute respiratory syndrome antibody booster booster dose Cohort studies collaboration coronavirus Coronavirus disease 2019 COVID-19 COVID-19 vaccine effective Effectiveness evaluate events fatigue Fever geometric GMTs help heterogeneous Heterologous heterologous booster dose higher risk homologous homologous booster dose Hospital admission immunogenicity interferon malaise myalgia neutralizing antibody Neutralizing titer Odds ratio outcome public health reduce resource review Safety Safety. SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 variant searched suggested symptomatic the vaccine vaccination Vaccine Vaccines variance model were used [DOI] 10.3390/ijerph191710752 PMC 바로가기
Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine RecipientsBNT162b2 또는 CoronaVac 백신 수혜자의 혈청에 의한 중증 급성 호흡기 증후군 코로나바이러스 2 오미크론 변이체의 중화Article Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Antibody titer Antibody titers Beta Beta variant beta variants BNT162b2 CoronaVac coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine Delta variants detectable Effectiveness elicited evade genome sequence geometric geometric mean GISAID database GMT GMTs Health Organization isolate Lineage Live virus microneutralization Mutation Nanopore nanopore sequencing neutralization Neutralizing Neutralizing antibodies neutralizing antibody Neutralizing antibody titer no significant difference not affect of BNT162b2 omicron Omicron variant Patient recipient recipients respiratory risk Risk assessment SARS-CoV-2 Sequencing sera severe acute respiratory syndrome Coronavirus significant difference significantly lower spike mutation strain Strains susceptibility TMPRSS2 Vaccine Vaccines variant Variant of concern. VeroE6 cells virus was determined whole genome sequence World Health Organization [DOI] 10.1093/cid/ciab1041 PMC 바로가기 [Article Type] Article
Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial6세 이상의 건강한 참가자를 대상으로 한 상동 프라임-부스트 요법을 사용한 재조합 아데노바이러스 5형 벡터 코로나바이러스 질병 2019(COVID-19) 백신의 안전성 및 면역원성: 무작위, 이중 맹검, 위약 대조, 2b상 시험Randomized Controlled Trial Published on 2022-08-242022-09-11 Journal: Clinical Infectious Diseases: An Official Publicat [Category] 임상, 진단, 치료기술, [키워드] Ad5-vectored COVID-19 vaccine Adenovirus adenovirus type-5-vectored COVID-19 vaccine Adults Adverse adverse events antibody Antibody Response boost children clinical Cohort coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccine dose double-blind elicited ELISA enrolled enzyme enzyme-linked immunosorbent assay event geometric mean geometric mean titer geometric mean titers GMT GMTs healthy homologous homologous prime immune response immune responses immunogenicity increasing age MIN neutralizing antibody participant phase phase 2b trial. Placebo placebo-controlled trial prime-boost regimen pseudovirus neutralizing antibody Randomized RBD receiving Receptor binding domain recombinant recombinant adenovirus robust Safe Safety SARS-CoV-2 single dose tolerable Trial vaccination Vaccine Viral viral particle [DOI] 10.1093/cid/ciab845 PMC 바로가기 [Article Type] Randomized Controlled Trial
Neutralizing Antibody Response to Pseudotype Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Differs Between mRNA-1273 and BNT162b2 Coronavirus Disease 2019 (COVID-19) Vaccines and by History of SARS-CoV-2 Infection유사형 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 중화 항체 반응은 mRNA-1273과 BNT162b2 코로나바이러스 질병 2019(COVID-19) 백신과 SARS-CoV-2 감염의 역사에 따라 다릅니다.Article Published on 2022-08-242022-09-12 Journal: Clinical Infectious Diseases: An Official Publicat [Category] SARS, 진단, [키워드] 19 2 95% confidence interval Antibody titer BNT162b2 BNT162b2 vaccine calculated coronavirus 2 CoV COVID COVID-19 Dilution dose geometric mean GMT GMTs highest history increase Infection inhibitory linear mixed-effects models mRNA mRNA COVID-19 vaccine mRNA vaccine mRNA-1273 mRNA-1273 vaccine NAb Neutralizing antibodies neutralizing antibodies. neutralizing antibody participant participants with SARS-CoV-2 prospective cohort pseudotype virus receiving respiratory response SARS SARS-CoV-2 SARS-COV-2 infection sera single dose Symptoms T Test tested uninfected participant uninfected participants vaccination Vaccine vaccine dose was collected [DOI] 10.1093/cid/ciab1038 PMC 바로가기 [Article Type] Article
Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial중국 성인에서 SARS-CoV-2 BNT162b1 mRNA 백신 접종 후 면역 지속성 및 안전성: 무작위, 위약 대조, 이중 맹검 1상 시험Clinical Trial Published on 2022-08-012022-09-12 Journal: Advances in therapy [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Administered Antibody titer BNT162b1 candidate vaccine Chinese COVID declined dose geometric mean titer GMT GMTs immune persistence maintain mRNA mRNA vaccine mRNA vaccine. NAb neutralizing antibody nucleoside-modified mRNA Older participant Participants persistence Phase 1 Registered reported Safety safety profile SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Event the vaccine vaccination vaccination schedule Vaccine was determined [DOI] 10.1007/s12325-022-02206-1 PMC 바로가기 [Article Type] Clinical Trial